- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -
BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC). The data show that fadraciclib substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDX). The data were presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.